"We anticipate the accuracy of SOLiD 4 and its ability to analyze whole transcriptomes will help us identify longitudinal biomarkers, which can signal development of progressive disease after a variable inactive or benign period of time," said Dr. Frazer.

The program aims to not only understand cancer progression, but to identify new potential targets for possible clinical trials in support of future targeted therapies in cancer. In addition to CLL, the UCSD Moores Cancer Center research program is currently sequencing triple negative breast tumors, lung tumors and primary central nervous system lymphomas using SOLiD technology in an effort to better understand these cancers.

"Life Technologies is proud to be working in conjunction with UCSD Moores Cancer Center, and supporting their biomarker research of hematological malignancies like CLL," said John L. Miller, President, Genetic Systems Division at Life Technologies. "Information generated from this research may lead to future studies and contribute to the development of new drug products with the intent to one day soon be able to treat these cancers in a more targeted approach."

The SOLiD 4 Sequencing System is one of the most advanced next-generation genomic analysis sequencing systems on the market and is used globally by researchers to better understand the genetic nature of diseases such as cancer, diabetes, and neurological disorders. Its throughput, accuracy, speed and flexibility allow researchers to generate up to 100 gigabases of high-quality mappable sequence data needed for the advancement of molecular medicine.

SOURCE Life Technologies Corporation